Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

37.76B

Market cap37.76B

Price-Earnings ratio

67.21

Price-Earnings ratio67.21

Dividend yield

—

Dividend yield—

Average volume

1.16M

Average volume1.16M

High today

$286.76

High today$286.76

Low today

$281.36

Low today$281.36

Open price

$283.35

Open price$283.35

Volume

116.09K

Volume116.09K

52 Week high

$495.55

52 Week high$495.55

52 Week low

$281.36

52 Week low$281.36

Stock Snapshot

With a market cap of 37.76B, Alnylam Pharmaceuticals(ALNY) trades at $282.80. The stock has a price-to-earnings ratio of 67.21.

As of 2026-06-15, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $281.36 and $286.76. The current price stands at $282.80, placing the stock +0.5% above today's low and -1.4% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 116.09K, compared to an average daily volume of 1.16M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $281.36 at its lowest and $495.55 at its peak.

ALNY News

TipRanks 3h

Alnylam: Hold Rating Reaffirmed as TTR Franchise Growth Offsets Slight Sales Shortfall; $370 Price Target Unchanged

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma on June 12 and set a price target of $370.00. Claim 55% Off TipRanks Unlock powerf...

Investing.com 3d

Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com

...

TipRanks 5d

Alnylam, GENESIS Pharma expand commercial partnership

GENESIS Pharma announced the expansion of its longstanding commercial partnership with Alnylam (ALNY) Pharmaceuticals. The extended agreement broadens the geogr...

Analyst ratings

71%

of 31 ratings

Buy

71%

Hold

29%

Sell

More ALNY News

Nasdaq 7d

Nasdaq 100 Movers: ALNY, MRVL

In early trading on Monday, shares of Marvell Technology topped the list of the day's best performing components of the Nasdaq 100 index, trading up 10.2%. Year...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Eli Lilly

Vertex Pharmaceuticals

Taiwan Semiconductor Manu…

Netflix

Novo Nordisk

Microsoft

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.